Roy Buchanan
Stock Analyst at JMP Securities
(5.00)
# 14
Out of 5,111 analysts
71
Total ratings
59.42%
Success rate
105.91%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $220.10 | -21.40% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $34.60 | +9.83% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $10.85 | +194.93% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $14.87 | +68.12% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.00 | +250.00% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.00 | +100.00% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.17 | +70.94% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.26 | +696.46% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $66.74 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.78 | +5.82% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $3.59 | +289.97% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $117.91 | -72.01% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.95 | +1.01% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $850.95 | -47.35% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $11.33 | +41.22% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.83 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $220.10
Upside: -21.40%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $34.60
Upside: +9.83%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $10.85
Upside: +194.93%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $14.87
Upside: +68.12%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.00
Upside: +250.00%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.00
Upside: +100.00%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.17
Upside: +70.94%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.26
Upside: +696.46%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $66.74
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.78
Upside: +5.82%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.59
Upside: +289.97%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $117.91
Upside: -72.01%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.95
Upside: +1.01%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $850.95
Upside: -47.35%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $11.33
Upside: +41.22%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.83
Upside: -